SYK-N
This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N
They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.
They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.
Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)
Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)
They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.
They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.
He has been watching them since $100. They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices. There is a rumour they may look to make a major acquisition. For a 5-10 year horizon, this is a great core holding. Yield %. (Analysts’ price target is unkown)
He has been watching them since $100. They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices. There is a rumour they may look to make a major acquisition. For a 5-10 year horizon, this is a great core holding. Yield %. (Analysts’ price target is unkown)
This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.
This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.
Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)
Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)
Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.
Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.
(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.
(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.
Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.
Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.
It is not as diversified as JNJ-N. He prefers ETFs to capture the theme because you don’t get the risk.
It is not as diversified as JNJ-N. He prefers ETFs to capture the theme because you don’t get the risk.
He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.
He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.
Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.
Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.
Hips, Knees and Ankles. They are capturing market share. He is seeing great take up here.
Hips, Knees and Ankles. They are capturing market share. He is seeing great take up here.
Seasonal strength is from the beginning of June until the middle of July and then goes sideways after that. We reached the end of the seasonal strength in the sector. You could hold until the next period of seasonal strength or sell it.
Seasonal strength is from the beginning of June until the middle of July and then goes sideways after that. We reached the end of the seasonal strength in the sector. You could hold until the next period of seasonal strength or sell it.
This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N